May 13, 2014

Eastern Virginia Medical School Study Indicates Major Glycemic Improvement in Subcutaneous Basal Bolus Insulin Delivery Using eGlycemic Management System

Poster presented during AACE shows improved outcomes using Glytec’s subcutaneous insulin dosing solution versus traditional basal bolus insulin therapy.

Glytec, a clinical information technology company solely dedicated to the mission of improving insulin management and glycemic control, is pleased to share the results of a late-breaking poster that was presented at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific and Clinical Congress. The poster is based on results experienced by Sentara Healthcare during the first 30 days after using Glytec’s Glucommander™ SubQ to manage subcutaneous Basal Bolus Insulin (BBI) therapy. The poster was presented by Joseph Aloi, MD, clinical director of the Strelitz Diabetes Center at Eastern Virginia Medical School, during the Congress’s general poster session.

May 7, 2014

Sentara Healthcare Ushers in a New Standard of Care in Glucose Management

Leading hospital system achieves dramatic reductions in occurrences of hyperglycemia and hypoglycemia, reduces length of stay.

Sentara Healthcare, a 12-hospital, not-for-profit health system serving Virginia and northeastern North Carolina, widely recognized for clinical excellence and IT innovation, today announced that they have achieved dramatic improvements in inpatient glucose management through the utilization of the eGlycemic Management System® (eGMS®), developed by Glytec.

May 14, 2013

Mountain States Health Alliance Achieves Dramatic Improvements in Glycemic Control with the Comprehensive Insulin-dosing Software Platform from Glytec

Thirteen-hospital system serving 29 counties in Tennessee, Virginia, Kentucky, and North Carolina applauds the solution for its integration, usability, and impact on patient care.

Glytec, a clinical information technology company dedicated to glycemic management solutions for hospitals and patients, today announced that Mountain States Health Alliance (MSHA) has experienced unprecedented clinical results in just the first 60 days of use of the inpatient glycemic control platform, Glucommander™.

May 22, 2012

Glytec Adds Pediatric Insulin Dosing to its IV and SubQ FDA Clearances

Glytec announced today that its Glucommander™ 2.0 Enterprise platform has been cleared by the FDA for pediatric use, ages 2 – 17.

Glytec’s Glucommander™ was the first insulin dosing software to be cleared for adult (ages 18+) intravenous use; it is the only company to achieve specific clearance for subcutaneous use, and now it is the only company cleared to offer this technology to hospitals caring for children.

May 2, 2012

Glytec Achieves ISO Certification

Glytec is the first company to achieve this medical device certification in the glycemic management product space.

Glytec, LLC, a privately held medical software company, announced that it has achieved the ISO 13485:2003 Certification for its quality management and assurance processes for the safe design, production and installation of Glucommander 2.0 Enterprise software.

September 19, 2011

GlucoTec, Inc. Completes Series A Preferred Stock Financing

Glytec will use the capital primarily to expand its direct US sales force, increase its international presence and advance research and development.

GlucoTec, Inc., the privately-held parent company of Glytec, LLC, today announced that it has completed a Series A Preferred Stock financing totaling $8,273,078.

May 11, 2011

Glytec Earns U.S. Department of Commerce Safe Harbor Certification for European Union

Glytec, a world leader in glycemic management solutions, has announced that it has achieved the U.S. Department of Commerce Safe Harbor Certification.

The Safe Harbor provides a legal framework allowing for protection of personal data generated from European countries and the safe transfer of data to the U.S. By certifying to the Safe Harbor, Glytec had demonstrated compliance with the Safe Harbor privacy principles accepted by all 27 member states of the European Union.

March 7, 2011

West Tennessee Healthcare Accelerates Optimum Inpatient Glucose Control with Glucommander Plus

The Glucommander Plus software provides healthcare professionals with individualized insulin dosing requirements for hospitalized patients.

Dave Roberts, MD, Vice President and Chief Medical Officer at West Tennessee Healthcare recently conducted a webinar presenting a systems approach to inpatient glucose control using the Glucommander Plus software from Glytec. The software includes many safety guardrails including predictive warning and alerts, a fully-integrated and real-time reporting engine, and precision bolus dosing of meal-time insulin.

November 1, 2010

Glytec Insulin Dosing Software Now Compatible with BlackBerry, Android, and iPhone

The G+ Enterprise Edition software is now compatible with select Android, BlackBerry, and iPhone devices, including the new iPhone 4 and iPad.

Glytec, LLC, a leader in glycemic management solutions, announced today that it has released a new enhancement to its inpatient blood glucose management software. The G+ Enterprise Edition software provides both intravenous and subcutaneous dosing recommendations of insulin and glucose and can be accessed from any computer within a hospital’s network. Users with mobile devices can now access real-time patient information, allowing for better monitoring of insulin dosing and blood glucose levels.

July 20, 2010

Glytec Announces FDA 510(k) Clearance on G+ Enterprise Edition Insulin Dosing Software

Glytec announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its G+ System Enterprise Edition, the next generation of the industry standard sophisticated insulin management software system.

The system incorporates new innovative features including certain algorithm enhancements, additional predictive warning and alerts, a fully-integrated and real-time reporting engine, and precision bolus dosing of meal-time insulin. The Enterprise Edition software provides both intravenous and subcutaneous dosing recommendations of insulin and glucose and can be accessed from any computer within a hospital’s network.